Introduction
Prostate cancer is a common malignancy in men, and its incidence continues to rise in many countries. 1 Screening for, and management of, early prostate cancer is one of the most challenging and controversial issues in medicine. In this Review, we discuss the evidence regarding risk assessment, early detection, and management of early prostate cancer, and identify the key issues for further research (fi gure). Improved identifi cation of risk factors to guide risk-adapted screening and preventive interventions is important. This Review also focuses on potentially modifi able lifestyle factors, and preventive therapies that might reduce risk. Prostate-specifi c antigen (PSA) screening for prostate cancer is controversial, and results from the CAP/ProtecT trial, 2 which is investigating PSA screening and three diff erent methods for treating early screen-detected lesions, are eagerly anticipated. Work is in progress to assess new tests that might be off ered either as part of primary screening, or for the triage of men with high PSA concentrations, and we discuss these tests in detail. Management strategies for low-grade cancers and for men with high PSA concentrations but negative biopsies are discussed. We assess new tests based on serum markers or tissue from needle biopsies and the role of multiparametric MRI, and outline the need for improved diagnostic methods. We conclude with a research agenda of areas most in need of further development and investigation.
Risk factors and biomarkers
Risk factors can be divided into non-modifi able factors (including known genetic mutations or polymorphisms, or specifi c genes not yet identifi ed), and external factors (including lifestyle factors when modifi cation might be possible). Blood-based markers, such as androgen levels or IGF-1, are not well established but are aff ected by both genetic and environmental factors.
Age, race, and geography
Age is the most important non-modifi able factor. In unscreened populations, prostate cancer has the steepest age-incidence curve of all cancers with a rapid increase in the seventh decade. 3, 4 Only 25% of prostate cancers are diagnosed before the age of 65 years in Europe. 1 Racial variation is pronounced: in the USA, compared with white men of European ancestry, black men of African ancestry have 58% greater incidence of prostate cancer and 144% greater mortality, whereas Hispanic men have 14% lower incidence and 17% lower mortality. 5 Substantial geographical variation has also been reported. Within Europe, incidence and mortality in Sweden is about twice of that in Spain and 1·5 times of that in Italy. 6 Incidence in immigrant populations from developing countries is lower than white populations in developed countries, suggesting that racial (genetic) factors are important. 7 Asian Indians and Pakistanis living in the USA have a standardised incidence ratio of 0·54 (95% CI 0·49-0·59) compared with American white populations. 7 However, the incidence in these immigrants is substantially higher than in their country of origin, which could be due, at least partially, to the absence of population screening in their country of origin or environmental factors. 7 Similar diff erences have been reported in immigrant populations in Sweden, although the diff erence in incidence reduced with increased length of stay, 8 suggesting that lifestyle is an important component of these diff erences.
Familial and genetic factors
The relative risk (RR) of developing prostate cancer is higher in men who have a fi rst-degree relative with prostate cancer (RR 2·48, 95% CI 2·25-2·74) than men without a fi rst-degree relative with prostate cancer. This risk is higher in men younger than 65 years who have a fi rst-degree relative than in older men with a fi rst-degree relative with prostate cancer (RR 2·87, 2·21-3·74 vs 1·92, 1·49-2·47; p interaction=0·002) and if the aff ected relative was a brother rather than a father (RR 3·14, 2·37-4·15). 9 Family history is important, but only 35% of the familial risk is explained by known genes. 10, 11 Although rare (about one per 300), a BRCA2 mutation confers up to 8·6 times increased risk in men younger than 65 years, and these mutations have been associated with aggressive cancer. 12, 13 Other rare mutations that confer greater RR of prostate cancer have been reported in BRCA1, HOXB13, NBS1, and CHEK2 genes. 13 The HOXB13 G84E mutation is the only other identifi ed mutation with a substantial RR (3-4 times), occurring in 1·3-1·4% of the general population. 14 Genome-wide association studies have uncovered more than 70 low-penetrance susceptibility loci (odds ratio [OR] per allele of 1·1-1·3) with high allele frequencies. 13 These loci are individually of little direct value, except for their potential to identify a mechanism of carcinogenesis, but if they act multiplicatively when used collectively in panels, they might improve risk stratifi cation; in such a case, they could identify 1% of the population with a RR of 4·7. 13 Possible familial risk factors for which the genetic basis is not known include some types of male pattern baldness 15 and digit length, 16 but their value in risk stratifi cation is unknown. Adult height has been associated with increased risk, with an OR of 1·06 for every 10 cm increase. 17
External exposure
Both ionising radiation 18 and ultraviolet radiation from sun exposure 19 have been linked to prostate cancer, but confi rmation of this link and more detailed risk estimates are needed. Increased risk in individuals exposed to cadmium has been reported, but high exposure is rare, and as such the risk is small with a negligible eff ect on public health. 20
Urinary tract infections
Risk for prostate cancer might be increased in men with a history of urinary tract infections. 21 There is evidence for a role for Trichomonas vaginalis, but evidence for other agents such as human papillomavirus and cytomegalovirus is weak. 22 Infections might aff ect the risk for prostate cancer by causing chronic intraprostatic infl ammation, and pathological studies show that infl ammation could be involved in the development of prostate cancer. 23 The role of urinary tract infections and chronic infl ammation in the development of prostate cancer is uncertain and more research is needed.
Smoking
Smoking is associated with a moderate increase in the risk for prostate cancer. 24 This association is much stronger, and the increase more pronounced, for aggressive or fatal cancers, particularly in current or heavy smokers who could have double or more risk as non-smokers. 25 Current smokers are at a higher risk of prostate cancer-specifi c mortality and recurrence than non-smokers and pastsmokers. The stronger association with aggressive cancers suggests that smoking might play a part in the promotion of metastatic spread. 25
Diet, weight, and physical activity
Increased body-mass index is associated with an increase in advanced prostate cancer but a decrease in localised disease, 26 which could explain the confl icting fi ndings in early reports. Analysis of the Prostate Cancer Prevention Trial (PCPT) showed similar fi ndings. 27 Although no clear links with specifi c dietary factors have been established, red meat, dairy protein, dietary fat, and coff ee 26 have been mentioned as factors. Sedentary lifestyle has been linked to high PSA concentrations in one large survey, 28 and a meta-analysis of 19 cohort and 24 case-control studies reported a small inverse relationship between physical activity and prostate cancer risk. 29 
Endogenous hormones
Prospective epidemiological studies have investigated the role of endogenous hormones in prostate cancer. A pooled analysis of individual patient data from 18 studies found no signifi cant associations with sex hormones, 30 but more data are needed to examine the relation with high grade cancer. 30, 31 For insulin-like growth factors (IGF), a pooled analysis of individual patient data from 12 studies showed a signifi cant positive association between circulating IGF-I and prostate cancer risk; 32 more data are needed for IGF-II and IGF-binding proteins.
Early detection of prostate cancer

PSA screening
The value of PSA screening is contentious. Five screening trials have been completed, but three are not of adequate quality to be informative; 33 the other two are of higher methodological quality. These two large trials, the Prostate,
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Modifi able and non-modifi able risk factors, pharmacological agents, and triage strategies for prevention and early detection of prostate cancer, many of which are yet to be established. IHC=immunohistochemistry. FISH=fl uorescent in-situ hybridisation. SNP=single-nucleotide polymorphism. 34 and the European Randomized Study on Screening for Prostate Cancer (ERSPC), 35 have reported diff erent results 36 possibly because of diff erences in design.
Risk factors and modifications
The PLCO trial was done in the USA, where PSA testing is common, and examined opportunistic versus organised annual screening. 36 Equal proportions of men in the opportunistic screening group (34·3% screened once and 9·8% two or more times) and annual screening groups (34·6% once and 9·4% two or more times) had undergone PSA testing within 3 years before recruitment to the trial. 34 Although the rate of PSA testing in the opportunistic screening group (40%) was lower than that in the annual screening group (85%) in the fi rst year, it increased to 52% in the sixth year. Men randomly assigned to the annual screening group had a higher incidence of prostate cancer (RR 1·12, 95% CI 1·07-1·17) but no reduction in prostate cancer mortality (1·09, 0·87-1·36). The absence of benefi t might not be entirely due to contamination (screening in the control group) in the control group because the results did not vary by PSAscreening status at baseline, but those men who were screened before recruitment had 25% lower risk of prostate cancer death than those who were not screened.
By contrast, the European ERSPC trial 35 examined the role of PSA screening in a largely unscreened population (7-30% of control men screened during the trial, depending on the trial centre) from seven countries with diff erent screening and treatment strategies. Overall, the investi gators noted a signifi cant 21% reduction (rate ratio 0·79, 95% CI 0·68-0·91, p=0·001) in death from prostate cancer in a predefi ned subgroup of men aged 55-69 years after 11 years of follow-up. Comparisons of treatments used in the two randomised groups have been done to explain the diff erences. 37, 38 More patients in the screening group (PSA screening every 2-4 years, interval between screens depending on the participating country) received radical prostatectomy and more in the control group (no intervention) were given hormone therapy, but this diff erence was largely explained by the worse tumour characteristics of the control group, as a result of their later diagnosis. 37 Treatment diff erences could not entirely explain the mortality benefi t. 37 Diff erences in screening interval and follow-up protocols exist between the two trials, but the major diff erence could be explained by the high screening rates in the controls of the PLCO trial. Three trials with lower methodological quality did not report a reduction in prostate cancer mortality. 33 A majority of the authors of this Review (62%) agree that PSA screening does reduce death from prostate cancer; others (GA, OWB, PHB, LGF, FCH, DI, LMM, HLP, BT, TJW, and AW) thought that the present evidence is not suffi ciently conclusive. We all agreed that the magnitude of the eff ect was uncertain and that substantial overdiagnosis and overtreatment exists, which needs to be reduced before recommendations for PSA screening in the general population can be made. The CAP/ProtecT trial of 450 000 men (ISRCTN92187251 and ISRCTN20141217) will report its initial fi ndings in 2016, and should clarify the value of PSA screening. The authors of this Review agree that death from prostate cancer should be the primary endpoint for screening studies. Although cause of death in older men can be diffi cult to ascertain, overall mortality has insuffi cient power because the number of deaths from unrelated causes is very large and substantially dilutes any eff ect. Every eff ort should be made to accurately identify the specifi c cause of death. Development of metastatic disease is a useful secondary endpoint, and it can provide earlier evidence of a screening eff ect if thoroughly assessed in both trial groups.
New triage and screening markers
A major focus of new research should be the development of new methods and markers to more clearly separate indolent (low-risk) cancers from aggressive, potentially lethal cancers, which will enable conservative management of more patients. Ideally, this would be achieved by non-invasive and inexpensive assays for biomarkers in serum (eg, Kallikrein proteins) or in urine (eg, PCA3 or TMPRSS-ERG fusions). Multiparametric MRI or assays that can be done on needle biopsies (such as the cell-cycle progression score) could be useful in safely avoiding radical treatments like prostatectomy or radiotherapy and the morbidity associated with these treatments.
Modifi cations of existing PSA-screening strategies such as changes in screening frequency and PSA thresholds could reduce harms from screening. Increasing the interval between PSA tests, from annual tests (as in the PLCO trial) to tests every 2-4 years (as in the ERSPC trial) might reduce harms from overdiagnosis without a detrimental eff ect on prostate cancer mortality. Similarly, data from population-based studies and randomised controlled trials, such as the Prostate Cancer Intervention Versus Observation Trial (PIVOT), support an increase in the threshold for abnormal PSA from 3-4 ng/mL to 6-10 ng/mL. 39 
Serum and urine markers
Several improvements to the most widely used PSA assay have been developed. Of these, the prostate health index, which is an assay based on the concentration of a molecular isoform of free PSA, 40 is much further along the biomarker discovery-credentialing-validation pathway, and has a greater specifi city than total PSA or percentage-free PSA. Addition of the Kallikrein protein hK2 to PSA-based markers has also improved the specifi city of PSA-based assays, 41 but both need further validation in a screening context, with a particular focus on their integration into screening algorithms and how they compare against present risk calculations.
Urinary markers need prostatic massage by digital rectal examination to obtain enough cells to be sensitive, Review which restricts their use to the triage of men at increased risk. The assays are complicated and require a specialist laboratory. Two assays have received the most attention. The PCA3 assay measures the non-coding prostate cancer gene 3 mRNA, 42 which is markedly overexpressed in prostate cancer cells, and produced only in prostate tissue. PCA3 is more specifi c than PSA, which is secreted by all prostate cells and is heavily aff ected by prostate volume. Initial fi ndings show that the PCA3 assay does identify cancer, but does not discriminate between lowrisk and aggressive disease. 43 A urinary marker that detects the fusion of TMPRSS2 with ERG is under development, and might better distinguish aggressive from low-risk early lesions. 44 Measurement in urine of gene fusions between ERG and other important genes, or multiplexing of PCA3 and TMPRSS2-ERG with genes such as SPINK1 and GOLPH2, is also of interest. Methylation markers might be useful for the diagnosis and prognosis of prostate cancer, but work is still at an early stage. Further research is needed to validate their use in needle biopsies and serum or urine samples.
The prostate health index, the four-marker Kallikrein panel, and PCA3 are more accurate than conventional PSA in the detection of cancer, mainly as a result of improved specifi city. 41, 45 PSA concentrations in men aged 40-60 years are predictive of which patients will develop prostate cancer several years later, and they might help to identify cancers that will become metastatic or lead to death. 46, 47 Further investigations are needed to improve screening and triage strategies.
Multiparametric MRI
Multiparametric MRI is a combination of high-resolution T2-weighted images and at least two functional MRI techniques-such as diff usion-weighted imaging, dynamic contrast enhancement, or MR spectroscopy-to improve specifi city. 48, 49 Compared with conventional MRI, multiparametric MRI provides better anatomical delineation, improved specifi city in characterisation of lesions, and a more reliable assessment of organ confi nement of the tumour to guide therapy. Whether multiparametric MRI can identify which Gleason 6 cancers can be safely managed by active surveillance is a key question. Multiparametric MRI highlights areas of aggressive disease, and improves staging by identifi cation of extracapsular extension or disease in anterior or apical locations, which might not be reliably established with digital rectal examination or standard systematic biopsies. 48 Apart from improved planning of curative treatments, multiparametric MRI could improve the selection of patients for active surveillance. Additionally, its potential to monitor patients managed by active surveillance should be investigated. 49 MRI-guided biopsies and MRI-transrectal ultrasound fusion-guided biopsies have higher detection rates for clinically relevant tumours than standard systematic biopsies. 49 Trials such as the Prostate MRI Imaging Study (PROMIS; ISRCTN 16082556) are likely to clarify when to use multiparametric MRI in the diagnostic pathway, and whether its use is cost eff ective. Incorporation of multiparametric MRI in models predicting cancer risk in patients with previous negative biopsy requires further study. 48, 49 
Markers in needle biopsies
Although done at a later stage, progression markers identifi ed in needle biopsies might help to avoid unnecessary radical treatment. Ki67 expression, as measured by immunohistochemistry, is the most used marker, and can distinguish between aggressive and indolent prostate cancer. 50 Immunohistochemistry and fl uorescent in-situ hybridisation (FISH) assays for PTEN, 51, 52 and FISH assay for TMPRSS2-ERG fusions have shown promise, 53 but with confl icting results. 54 Similarly, overexpression of MYC 55 by FISH and TP53 56 by immunohistochemistry have some prognostic potential. A four-protein signature-PTEN, SMAD4, cyclin D1, and SPP1-identifi ed with immunohistochemistry predicts biochemical recurrence. 57 A cell-cycle progression score (Prolaris, Myriad Genetics), which has stronger prognostic value than current prognostic biomarkers such as Gleason grade, PSA level, and extent of disease, was predictive of outcome in several studies of transurethral resection of the prostate, needle biopsy, and radical prostatectomy specimens. 58 Because this material contains more tumour cells and their components than a serum or urine sample, the potential for improved assessment exists. However, inadequate sampling is a problem with needle biopsies, especially when few cores are taken, and the performance of various assays in 12-core or template biopsies is an important research area. Other mRNA marker panels have been used with some success, often containing PTEN, p53, or TMPRSS2-ERG. 59 
Management of men with raised PSA concentrations
An important issue is how best to manage men with raised PSA concentrations who have had negative biopsies. Study fi ndings 60, 61 show a high incidence of prostate cancer during follow-up after negative biopsy. The Göteborg sub-cohort of the ERSPC trial showed a 26% incidence within 4 years, 61 whereas 10% of such men in the PLCO trial developed prostate cancer within 3 years of negative biopsy. 60 The placebo group of the Prostate Cancer Prevention Trial (PCPT) had high positive rates (15% overall) for cancer in biopsies of men with normal PSA concentrations at the end of a 7-year study period. 62 Use of additional markers such as Kallikrein panels for triage of such men needs further investigation. 41
Management of low-grade prostate cancer
An equally important issue is the management of men with low-grade (eg, Gleason score 6) cancer. Gleason 6 is poorly defi ned, and its natural history and the appropriate www.thelancet.com/oncology Vol 15 October 2014 e488 Review active surveillance protocols need to be refi ned and clinically validated.
Role of observation
In selected low-risk subgroups of the PIVOT trial, 39 passive observation led to the same prostate cancer mortality as radical prostatectomy, and observation alone is an important management option. In SPCG-4, the radical prostatectomy group had reductions in prostate cancer death, all-cause mortality, and development of distant metastases, but only the eff ect on distant metastases was statistically signifi cant in men aged 65 years or older. 63 Apart from morbidity and mortality related to radical treatment, observation alone also avoids biopsy-related morbidity associated with active surveillance. The challenge is to identify as large a subgroup as possible that can be safely managed this way. New markers to identify aggressive cancers need to be developed and validated, especially in men with Gleason 6 cancer and PSA less than 10 ng/mL.
Preventive therapy
Role of 5α-reductase inhibitors
The use of 5α-reductase inhibitors either for prevention or management of early disease has produced complex outcomes. The PCPT 64 investigated fi nasteride in men with low PSA (≤3 mg/mL) and no evidence of disease. Biopsies were recommended at the end of the study or if digital rectal examination was abnormal and PSA exceeded 4·0 ng/mL in the control group or 2·0 ng/mL (1·75 ng/mL after fi rst 4 years) to allow for the reduction of PSA level with this drug. After 7 years of follow-up, a 24·8% reduction (95% CI 18·6-30·6) in overall prostate cancer incidence was reported compared with the control (placebo) group, but this eff ect was restricted to cancers with a Gleason score of 6 or less, and an increase of 27% in high-grade tumours was noted (RR 1·27; 95% CI 1·07-1·50). Similar results were reported in the REDUCE trial, 65 which assessed dutasteride, another 5α-reductase inhibitor, in a high-risk population of men with a PSA concentration between 2·5 ng/mL and 10 ng/mL and a negative initial prostate biopsy. After 4 years of follow-up, a 23% reduction in overall prostate cancer incidence was reported compared with controls who received placebo, but there was no eff ect on cancer with Gleason score 7 or above, and there was an increase in Gleason 10 tumours. Although both drugs have a benefi cial eff ect on benign prostatic disease, the absence of eff ect on high-grade cancer is a major concern. An increase in the sampling accuracy of the prostate with the then common six-needle biopsy, because of smaller total prostate size, has been off ered as an explanation for this fi nding. 66 Investigators of a large population-based case-control study also reported a signifi cantly lower risk of cancer with Gleason scores 2-7 in men given 5α-reductase inhibitors compared with age and county matched men in the general population who did not receive these drugs; however, by contrast with the randomised controlled trials, no evidence of an increased risk of cancer with Gleason scores 8-10 was detected. 67 Prevention of low-risk prostate cancer is benefi cial because it avoids harm related to diagnosis and treatment, and it might even be cost eff ective; 68 however, neither fi nasteride nor dutasteride have been approved by the Food and Drug Administration for cancer prevention. Long-term results from the PCPT have confi rmed their earlier fi ndings, and 15-year overall survival rates were similar in both groups even though more high-grade prostate cancers were diagnosed in the fi nasteride group than the placebo group. 69 However, the trial had insuffi cient power to detect a diff erence in overall survival. It is important to note that, for individuals on 5-α-reductase inhibitors, clinicians should adjust the PSA biopsy thresholds by 50% 70 because these agents lower PSA values. Retrospective analysis of data from the REDUCE trial has shown that PSA maintains its predictive value for men on dutasteride when lower biopsy thresholds are used than for men not taking this drug. 71 Dutasteride was used as an adjuvant treatment in the REDEEM trial of 302 men (289 evaluable) with Gleason 5-6 cancer managed by active surveillance. 72 After 3 years of follow-up, a 38% reduction (hazard ratio [HR] 0·62, 95% CI 0·43-0·89) in progression was reported with dutasteride but no metastatic disease or prostate cancer-related deaths were reported in either group. A large trial with longer follow-up is needed to assess 5α-reductase inhibitors for the prevention of aggressive prostate cancer.
Other preventive agents
Trials of dietary agents thought to have a benefi cial eff ect on prostate cancer have been negative. 73 Randomised studies of β-carotene for those at high risk of lung cancer showed an increase in lung and stomach cancers. 74 Investigators of another study with prostate cancer as the primary endpoint, the SELECT trial, 75 reported that in 35 533 men with PSA of 4 ng/mL or less and a negative digital rectal examination, neither selenium nor vitamin E supplementation had a benefi cial eff ect on the incidence of prostate cancer; incidence of prostate cancer increased with vitamin E dietary supplementation.
A short-term study of the polyamine synthesis inhibitor difl uoromethylornithine 76 noted signifi cantly lower polyamine content in the prostate within 1 month, that suppression of prostate putrescine concentrations was maintained, and that the rate of prostate growth was decreased at 12-month follow-up compared with placebo. Further long-term follow-up studies are needed.
Evidence for other preventive or therapeutic interventions is scarce and comes from epidemiological studies and randomised trials in which prostate cancer was a secondary endpoint. Aspirin has the most promising profi le, and fi ndings from case-control and cohort studies 77 suggest a small but consistent reduction in disease incidence of about 10%. A meta-analysis of randomised Review controlled trials 78 reported a larger but non-signifi cant reduction in mortality in patients taking aspirin regularly (19%, p=0·12), compared with controls who did not take regular aspirin, suggesting that aspirin is of benefi t for aggressive tumours. This fi nding has been corroborated in the Health Professionals Follow-up Study, which noted a 16% reduction (HR 0·84, 95% CI 0·69-1·02) in lethal prostate cancers (cancer death or metastasis) in patients who took aspirin regularly as opposed to those who did not. 79 These studies were undertaken in individuals at average risk for prostate cancer, with or without cardiovascular risk factors, and further studies of highrisk individuals and those with tumours of Gleason score 7 or above are needed. Aspirin could exert an eff ect through an antiplatelet mechanism to slow metastatic spread and improve survival, but eff ects through other pathways have been proposed. 79 A range of adjuvant trials in diff erent tumour types including prostate cancer are either underway (ClinicalTrials.gov identifi ers NCT00565708 and NCT01058902) or being planned. A meta-analysis of observational studies shows that statins have a benefi cial eff ect in reducing the incidence of prostate cancer, particularly advanced disease. 80 However, reduction in the incidence of prostate cancer has not been seen with longterm statin use and when data from randomised controlled trials are considered. 81 Residual confounding due to health awareness in statin users and screening frequency probably underlies the observational studies' fi ndings; any benefi cial eff ect is unclear in the absence of long-term follow-up data, and so further research and longer followup of randomised controlled trials are needed.
Studies of other dietary supplements have not been very promising. Vitamin D showed promise in initial epidemiological studies, but recent work has been negative. 82 However, several studies are underway and they need to be completed before a full conclusion can be reached. 83 Lycopene, an open-chain carotenoid found in cooked tomatoes showed initial promise, but a systematic review of all randomised controlled trials has not shown any overall eff ect, 84 although data are still sparse. Metaanalysis of observational data indicates no overall eff ect with low-to-moderate intake, but a potential eff ect with high lycopene intake (RR 0·89, 95% CI 0·81-0·98), 85 although the evidence is very scarce. The naturally occurring isothiocyanate sulforaphane that is found in broccoli and other cruciferous vegetables is being investigated (ClinicalTrials.gov identifi ers NCT01265953 and NCT00946309).
Research and policy agenda
Research should focus on developing better biomarkers for identifi cation of aggressive disease. Urinary markers such as PCA3 and TMPRSS2-ERG are the most developed, but still require further validation. Multiparametric MRI has potential to identify the highest grades of lesion and guide biopsies to be taken from the most aggressive regions, especially in men with high PSA concentrations, but further studies are needed. Once a biopsy sample has been taken, expression profi le panels such as the cell-cycle progression score could be used to determine tumour aggressiveness, but they need to be assessed in a range of contexts based on the treatment options under consideration and combinations with other more standard markers of tumour aggressiveness. A substantial proportion of cases with high PSA or cases identifi ed as high risk by conventional means do not progress or cause death. Biomarkers that show indolent disease are needed to identify men who can be spared treatment and its adverse eff ects. When better biomarkers become available, future studies of modifi able risk factors should focus on those associated with aggressive prostate cancer.
Careful consideration of the population who would benefi t from screening is needed. Men older than 70 years or younger men with serious comorbidities are not good candidates. Lengthening of the screening interval to every 2-4 years might reduce harms without substantially reducing benefi ts. Primary screening markers that improve specifi city are needed, and assays such as PHI and the four-marker Kallikrein panel need to be assessed in the appropriate clinical setting.
Additionally, further research is needed into the appropriate treatment and management of individuals without cancer but who are at high risk (often due to high PSA but negative biopsy), those with low-grade tumours (Gleason 6 and PSA <10 ng/mL), or those with a genetic predisposition to prostate cancer. Although aspirin is one of the more promising agents, more studies of dietary supplements including vitamin D, difl uoromethylornithine, lycopene, and sulforaphane are warranted. Despite the many issues that remain unresolved, further study of the 5α-reductase inhibitors will be diffi cult because of the small increase in highgrade cancers in two randomised controlled trials and prohibitively large sample size needed to see a mortality reduction.
Conclusions
Evidence for several of the modifi able prostate cancer risk factors is uncertain. However, lifestyle modifi cations such as smoking cessation and exercise can decrease the
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